Any current/future new fundraising through debt or equity?

Currently, Hester Biosciences has no plans for taking additional debt or loans. The company is at its highest borrowing level, but the debt is expected to reduce over time. No additional capital expenditure (capex) is required for ongoing projects at present. Approximately Rs.10-12 Crores payable for existing capital creditors related to current projects. Any new capital expenditure or fund raising would be a different situation, but currently, they are fully covered for expansions with invested capital. Grants related to specific projects may continue to come but not considered as regular fun

Any current/future capex/capital investment/strategic investment?

No significant additional capex is currently planned for ongoing projects; only Rs.10-12 Crores payable for existing capital creditors. Fill-finish facility under construction expected to commission within ~60 days; this will double vaccine capacity in India. BSL-III laboratory (COVID bulk antigen manufacturing) facility being repurposed post-COVID. Capital already invested covers current expansion potentials: Rs.50 Crores in Nepal, $25-30 million (~Rs.200 Crores) in Africa, and an additional Rs.200 Crores capacity potential in India. Any new capital investment would be situational and

Future growth expectations in sales/revenue/volumes?

Target to achieve Rs.600 Crores revenue in approximately 3 years through current capacity in India, Nepal, and Africa (Rajiv Gandhi). African subsidiary in Tanzania expected to ramp up to $25 million sales in 4-5 years, leveraging existing capacity (Rajiv Gandhi). Poultry vaccine sales showing recovery, following an industry downturn; expectation of industry improvement from current low levels (Rajiv Gandhi). Health products growing rapidly (60% increase quarter-on-quarter) though currently smaller base; focus on increasing cycles of health products to drive EBITDA growth (Rajiv Gandhi).

Future growth expectations in earnings/operating earnings/profits/EPS?

Hester Biosciences aims to restore and improve margins to previous levels despite current challenges, combining both vaccine and health product sales. Management is optimistic about revenue growth, expecting a higher growth rate this year compared to last year. The poultry division is anticipated to recover from its current low phase, showing improvement quarter-on-quarter. Health products and pet care business are viewed as growth drivers, with the pet segment growing ~20% YoY, faster than poultry or animal healthcare. New immunization programs like the Government's PPR vaccination te

Current/ Expected Orderbook/ Pending Orders?

Hester Biosciences currently has orders in hand worth around Rs.15 Crores in Nepal. Various tenders are in process in Nepal, indicating ongoing order activity. There is a mention of unexecuted orders for the PPR vaccine, due to a shift in government focus to lumpy skin disease, expected to be fulfilled soon. Immunization programs impact quarterly sales based on the timing of government orders, causing some variability in order execution. The company is also targeting the domestic market alongside tender-based business, with increasing revenues expected from this segment.

Hester Biosciences LtdQ4 FY23Pharmaceuticals & Biotechnology

Hester Biosciences Ltd Q4 FY23 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹2,307.6P/E: 36.9Market Cap: ₹2.0K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Order

Capex

0 of 5 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

Target to achieve Rs.600 Crores revenue in approximately 3 years through current capacity in India, Nepal, and Africa (Rajiv Gandhi).
African subsidiary in Tanzania expected to ramp up to $25 million sales in 4-5 years, leveraging existing capacity (Rajiv Gandhi).
Poultry vaccine sales showing recovery, following an industry downturn; expectation of industry improvement from current low levels (Rajiv Gandhi).
Health products growing rapidly (60% increase quarter-on-quarter) though currently smaller base; focus on increasing cycles of health products to drive EBITDA growth (Rajiv Gandhi).
Pet care business is a sunrise industry in India, growing at around 20% YoY, with significant future potential due to increase in pet ownership (Rajiv Gandhi).
Immunization programs like Government of India’s PPR program (Rs.40 Crores tender) expected to boost sales (Priya Gandhi).
Overall optimistic about revenue growth higher than last year with improved bottom lines.

Margin guidance

Category 3

Hester Biosciences aims to restore and improve margins to previous levels despite current challenges, combining both vaccine and health product sales.
Management is optimistic about revenue growth, expecting a higher growth rate this year compared to last year.
The poultry division is anticipated to recover from its current low phase, showing improvement quarter-on-quarter.
Health products and pet care business are viewed as growth drivers, with the pet segment growing ~20% YoY, faster than poultry or animal healthcare.
New immunization programs like the Government's PPR vaccination tender (Rs.40 Cr order) will boost sales in the coming year.
African and Nepal subsidiaries plan gradual capacity ramp-ups, targeting $25M revenue in Africa over 4-5 years.
Overall, the company expects sales to increase, profit margins to improve, and sustainable growth over the next 3 years with a target of Rs.600 Cr revenue expansion.

See what Hester Biosciences Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

Currently, Hester Biosciences has no plans for taking additional debt or loans.
The company is at its highest borrowing level, but the debt is expected to reduce over time.
No additional capital expenditure (capex) is required for ongoing projects at present.
Approximately Rs.10-12 Crores payable for existing capital creditors related to current projects.
Any new capital expenditure or fund raising would be a different situation, but currently, they are fully covered for expansions with invested capital.
Grants related to specific projects may continue to come but not considered as regular fundraising.
Overall, no planned fundraising through debt or equity in the near term based on management comments.

Order book

Hester Biosciences currently has orders in hand worth around Rs.15 Crores in Nepal.
Various tenders are in process in Nepal, indicating ongoing order activity.
There is a mention of unexecuted orders for the PPR vaccine, due to a shift in government focus to lumpy skin disease, expected to be fulfilled soon.
Immunization programs impact quarterly sales based on the timing of government orders, causing some variability in order execution.
The company is also targeting the domestic market alongside tender-based business, with increasing revenues expected from this segment.

See what Hester Biosciences Ltd management said on order book — free account, 30 seconds.

Capex plans

No significant additional capex is currently planned for ongoing projects; only Rs.10-12 Crores payable for existing capital creditors.
Fill-finish facility under construction expected to commission within ~60 days; this will double vaccine capacity in India.
BSL-III laboratory (COVID bulk antigen manufacturing) facility being repurposed post-COVID.
Capital already invested covers current expansion potentials: Rs.50 Crores in Nepal, $25-30 million (~Rs.200 Crores) in Africa, and an additional Rs.200 Crores capacity potential in India.
Any new capital investment would be situational and unlikely at this moment.
Grants related to specific projects (like COVID) may continue but are project-specific, not recurring.
Overall, the company is capital-ready to support growth without needing substantial new capex immediately.

Track Hester Biosciences Ltd — get its next earnings analysis in your feed

How does Hester Biosciences Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisHester Biosciences Ltd

Rev 3Mar 3

See where Hester Biosciences Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Hester Biosciences Ltd rank in Pharmaceuticals & Biotechnology?

Compare Hester Biosciences Ltd against every Pharmaceuticals & Biotechnology company (Q4 FY23) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Hester Biosciences Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Lincoln Pharmaceuticals Ltd (Q2 FY27)
2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it
Alivus Life Sciences Ltd (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest
Strides Pharma Science Ltd (Q2 FY27)
Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation
Laurus Labs Ltd (Q2 FY27)
2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Hester Biosciences Ltd Q4 FY23 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does Hester Biosciences Ltd rank in Pharmaceuticals & Biotechnology?

Continue your research

What Hester Biosciences Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season